{"ok":true,"entity":{"id":"bridgebio-pharma","name":"BridgeBio Pharma","entityType":"company","officialName":"BridgeBio Pharma, Inc.","canonicalName":"BridgeBio Pharma","displayName":"BridgeBio Pharma","category":"遺伝性疾患向けバイオ医薬品企業","shortDescription":"BridgeBio Pharma, Inc.（Nasdaq: BBIO）は、カリフォルニア州パロアルトを拠点に遺伝性疾患向けの医薬品を開発する商業段階のバイオ医薬品企業。Attruby（acoramidis）とNULIBRYを医薬品として掲げ、2026年第2四半期の純売上高合計は2億4,370万米ドル。BBP-418など3件のNDAがFDAで審査中で、2026年10月時点でいずれも未承認。","primaryCluster":"biotech-genomics","parentEntity":null,"verificationStatus":"draft","website":"https://www.bridgebio.com/","updatedAt":"2026-10-22T11:50:32.298Z","secondaryClusters":[],"alias":["BridgeBio"],"searchKeywords":["BridgeBio","ブリッジバイオ","Attruby","acoramidis","アコラミジス","遺伝性疾患","BBIO","ATTR-CM"]},"referenceIndex":["P-01-001","P-02-001","P-04-001","P-05-001","P-06-001"]}